FDA Publishes Revised Guidance on Reprint Practices for Off-Label Drugs and Medical Devices

By Jaclyn Jaeger2014-03-17T14:52:00

lock icon THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.

Become a Member

News and analysis for the well-informed compliance or audit exec. Select an option and click continue.

Annual Membership $499 Value offer

Full price one year membership with auto-renewal.

Membership $599

One-year only, no auto-renewal.

Access CW Newsletters and CPE webcasts. REGISTER FOR LIMITED FREE ACCESS

Already a Compliance Week member?

Article
The EpiPen controversy’s bad omens for pharmas

2016-09-27T12:45:00Z By Joe Mont

At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.
Article
Detecting corruption in the pharmaceutical sector

2016-06-21T14:00:00Z By Jaclyn Jaeger

Jaclyn Jaeger looks at a new report from Transparency International that aims to help companies in the pharmaceutical industry detect and prevent corruption.
Article
FDA Guidance Provides Clarity to Drug and Medical Device Companies

2014-04-01T00:00:00Z By Jaclyn Jaeger